XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $556K invested in XTL Biopharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 0.01% → 0% (-0.01%)
9% less capital invested
Capital invested by funds: $613K → $556K (-$57K)
25% less funds holding
Funds holding: 4 → 3 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$2.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$36.6K |
| 2 |
Morgan Stanley
New York
|
-$17.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $477K | – | – | – |
|
|
2
Morgan Stanley
New York
| $63.6K | -$17.5K | -1,675 | -20% |
|
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $15.8K | +$2.44K | +234 | +17% |
|
|
4
Citadel Advisors
Miami,
Florida
| – | -$36.6K | -3,859 | Closed |
|
XTLB Hedge Fund Activity: Q3 2024 in Review
3 of the 6,970 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2024, worth a combined $556K — down 9.3% from $613K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was RhumbLine Advisers, adding an estimated $2.44K. The largest seller was Citadel Advisors, exiting entirely with an estimated $36.6K sold.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2024, down from 4 in Q2 2024.
- Funds reported $556K of XTL Biopharmaceuticals stock for Q3 2024, down 9.3% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q3 2024 and 1 closed out, a net change of -1 holder.
- The largest XTL Biopharmaceuticals buyer in Q3 2024 was RhumbLine Advisers, an estimated $2.44K added.
- The largest XTL Biopharmaceuticals seller in Q3 2024 was Citadel Advisors, an estimated $36.6K sold.
Based on aggregated 13F filings for Q3 2024.